Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 6 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
12 Jan 2020
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.

Oral corticosteroid use during pregnancy poses no risk of congenital heart defects

26 Nov 2019

Exposure to oral corticosteroids during pregnancy bears no harm to the offspring in terms of the risk of congenital heart defects (CHDs), a study reports.

Using data from a register-based nationwide prevalence study including all live singleton births in Denmark, researchers looked at 1,194,687 mother-and-child pairs to assess the risk of offspring CHDs in relation to the mothers’ use of oral corticosteroids in early pregnancy.

A total of 2,032 individuals (0.17 percent) had a mother who filled a prescription for oral corticosteroids during the 0–8-week period after conception, whereas 1,142,091 (96 percent) had a mother who never used the drugs.

CHDs were documented in 11,094 individuals, yielding a prevalence rate of 93 per 10,000. The crude prevalence was higher in individuals whose mothers filled a prescription for oral corticosteroids in weeks 0–8 after conception than in those whose mothers were never exposed to the drug (32 vs 10,534; prevalence, 157 vs 92 per 10,000; prevalence ratio [PR], 1.72, 95 percent confidence interval [CI] 1.21–2.44).

However, the PR was attenuated following adjustments for maternal age, birth order, calendar year and other covariates associated with corticosteroid exposure and CHD (1.29, 95 percent CI, 0.90–1.84; p=0.16). Propensity score-matched analysis yielded similar results (PR, 1.38, 95 percent CI, 0.95–2.02).

In light of the findings, the researchers pointed out that there is no reason to refrain from corticosteroid treatment during early pregnancy, especially when there is a clear and pertinent indication.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 6 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
12 Jan 2020
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.